Mathieu Losguardi’s Post

As we look ahead to 2024, one trend in biotech that's gaining momentum is the increased focus on CNS, neuroscience, and mental health by big pharmaceutical companies. What's particularly intriguing is the pivotal role small molecules are playing in this shift. Companies like Neumora Therapeutics and Karuna Therapeutics are at the forefront, leveraging the power of small molecules to unlock new treatments for complex conditions like major depressive disorder and schizophrenia. Neumora's Navacaprent, a selective kappa opioid receptor antagonist, and Karuna's KarXT, a muscarinic acetylcholine receptor agonist, are prime examples of how small molecules can be tailored to target specific neural pathways, offering new hope for patients and potentially transforming the landscape of CNS therapeutics. This focus not only highlights the versatility and potential of small molecules in addressing intricate CNS disorders but also underscores a broader commitment to advancing mental health treatments. As we move forward, it's clear that the understanding and application of small molecules will be a key driver in the next wave of CNS therapeutics. Let's keep an eye on this exciting frontier! #Biotech2024 #CNS #Neuroscience #MentalHealth #SmallMolecules #Innovation

🚀 Exciting News in Neurorestoration! Myrobalan Therapeutics Secures $24M in Series A Funding! 🌐💡 Thrilled to share that Myrobalan Therapeutics has successfully completed a $24 million Series A funding round led by Co-win Ventures! 🎉 This funding will propel the development of potentially groundbreaking CNS therapeutics targeting remyelination and anti-neuroinflammation. 🧠💊 🌟 Key Highlights: Series A Funding: $24 Million Leading Investors: Co-Win Ventures, Guan Zi Equity, 3E Bioventures, AB Magnitude Ventures Group Innovative Approach: Focused on Novel Mechanisms for CNS Repair Targeting Multiple Diseases: MS, Alzheimer’s, ALS, Rare Neurological Conditions 🔬 Myrobalan's Unique Position: Myrobalan is revolutionizing CNS drug development with highly selective compounds addressing challenging targets associated with demyelination and neuroinflammation. 🎯 The potential applications span across multiple debilitating conditions, offering hope for patients with unmet medical needs. #MyrobalanTherapeutics #Neurorestoration #SeriesAFunding #InnovationInHealthcare #CNSResearch #BiotechBreakthroughs

Did you hear Enveric Biosciences, Inc. presented compelling preclinical data on their lead compound, EB-003, at the 7th Neuropsychiatric Drug Summit? EB-003 is a neuroplastogenic, non-hallucinogenic DMT analog designed to provide therapeutic benefits for anxiety and depression without the typical psychedelic side effects. Their research demonstrates its potential to reduce anxiety and depression in preclinical models while maintaining optimal brain exposure levels after oral dosing. “EB-003’s unique profile and promising data set it apart from other DMT-based drugs in development, making it a key value driver for Enveric and our shareholders,” shared Joseph Tucker, Ph.D., CEO of Enveric. Read more about their research! 🔗 https://buff.ly/3N9mMnb $ENVB #NeuropsychiatricSummit #MentalHealthInnovation #EB003 #PsychedelicResearch #FutureOfMedicine #DrugDevelopment #Neuroplasticity

#Biopharma industry's #MandA focus in Q4 2023 was primarily on oncology, but we expect neurology and cardiometabolic indications to gain traction in 2024. Explore the insights into these therapeutic area trends in this new article. #PharmaDeals #BIOEurope24 #StrategicAcquisitions https://bit.ly/4aZPFvT

🚀 Exciting news in the field of CNS therapeutics! Myrobalan Therapeutics, a pioneering biotechnology company, has successfully secured $24M in a Series A funding round led by Co-Win Ventures, with participation from esteemed investors like Guan Zi Equity Investment Partnership, AB Magnitude Ventures Group, and 3E Bioventures Capital. 💸 The funds will be instrumental in advancing Myrobalan's mission to develop groundbreaking drugs for the central nervous system (CNS) with restorative potential. Overcoming historical challenges in CNS drug development, Myrobalan focuses on creating brain-penetrant, highly selective, and orally available products. 💊 The compounds developed by Myrobalan target new mechanisms associated with demyelination and neuroinflammation, linked to conditions like multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s disease, and other rare neurological ailments. 🧠 CEO and co-founder, Dr. Jing Wang, expressed confidence in their approach, stating, "Our deep understanding of remyelination and neuroinflammation has broad application in high-unmet need CNS diseases." 🌐 Myrobalan's portfolio includes an antagonist to G-protein coupled receptor 17, addressing remyelination, and a colony-stimulating factor-1 receptor inhibitor, targeting demyelination and neuroinflammation. Additionally, an inhibitor of allosteric tyrosine kinase 2 is in the pipeline to lower neuroinflammation. 🔬 These oral neurorestorative drugs aim to fix damage and reinstate neural function in degenerative CNS ailments with high unmet needs. Dr. Xin Huang, Managing Partner at Co-win Ventures, expressed pride in supporting Myrobalan's work, stating, "Myrobalan has the potential to change the narrative for patients with CNS disease." 🌟 With a robust pipeline, strategic partnerships, and compelling preclinical data, Myrobalan is poised to advance its neurorestorative candidates into clinical trials. #Biotech #CNSResearch #Innovation #Healthcare 🌈💊

Looks like Kyverna Therapeutics has laid the foundations for the next major IPO of 2024. Here's a breakdown of how the $180 M will be utilized: • approximately $150.0 million to advance the clinical development of KYV-101, Kyverna's lead product candidate, in two broad areas of autoimmune disease: rheumatology and neurology, including completion of enrollment for our KYSA-1 Phase 1 trial, continued enrollment for our KYSA-3 Phase 1/2 trial, and initiating enrollment for KYSA-5, KYSA-6, and KYSA-7 clinical trials;    • approximately $20.0 million to advance KYV-201 through preclinical development and into clinical development; and    • the remainder to fund expenses associated with research and development and additional clinical development, and for general corporate purposes, working capital and capital expenditures. #cellandgenetherapy #biotechnology #cellandgenetherapies #ipo

⏱️Just 3 days to go until the o2h chaitime portfolio pitch day! Spotlight on the last company presenting - PharmEnable Therapeutics. PharmEnable Therapeutics is accessing the inaccessible by reimagining small molecules through AI. They develop innovative drugs against targets that require the specificity of biologics, but that cannot be addressed by them due to physical access barriers. With their proprietary AI-enabled platform chemSEEK, they map unexplored chemical space and discover novel small molecules with antibody-like specificity and selectivity. PharmEnable has a discovery stage pipeline in oncology and neurology, as well as engaging in partnerships across disease areas. They raised a $7.5M funding round in 2023 led by MP Healthcare. They also recently expanded their partnership with Sosei Heptares to include a second neurology programme. 👉Join us for o2h chaitime portfolio pitch day and watch Hannah Sore as she shares insights into the company’s current undertakings. Secure your seat now by registering for the event - https://lnkd.in/gWUpg4Xd   #o2hVentures #eis #seis #portfolio #seedingnewideas

🚀 Explore how San Diego-based biotech, Libra Therapeutics, accelerates neurodegenerative drug development with a completely virtual setup. 🧠💉 Dive into Libra’s discovery and lead optimization workflow, focusing on their lead program targeting TRPML1 for CNS degenerative disorders. Get insights into their biomarker-oriented approach and the potential for clinical hypothesis testing. 🔬 Leveraging data through Collaborative Drug Discovery - CDD VAULT, Libra seamlessly collaborates with international CROs, advancing its TRPML1 program toward Phase 1 clinical trials in 2025. 💊📊 Discover the flexibility, functionality, and security provided by CDD Vault, empowering Libra in the dynamic realm of biomarker-oriented drug development in our latest article. 👇️ https://lnkd.in/dKj3abuq #biotechinnovation #drugdevelopment #neurodegenerativediseases #virtualbiotech #clinicaltrials #datamanagement #biomedicalresearch #healthcareadvancements #neuroscience #biotechcollaboration

🔬 Tom's Top 3 - Ep. 2! 🚀 What's happened over the last week... Follow along for the updates! 👉 Q1's Fierce Biotech Layoff Analysis! In 2024, the biotech sector faces ongoing challenges, with persistent layoffs reflecting the aftermath of the 2023 bear market. Despite hurdles, companies remain resilient, navigating uncertain conditions and clinical trial setbacks. 💡 Spanish pharmaceutical giant Ferrer makes waves in AI-driven neuroscience research with a $122 million deal securing rights to Verge Genomics' clinical-stage ALS therapy. This strategic move underscores Ferrer's commitment to innovative treatments, positioning them to address critical medical needs and fill pipeline gaps. 🌟 Ipsen Pharmaceuticals enters the ADC race with a $900 million deal, marking a significant milestone in oncology research. This strategic move highlights Ipsen's dedication to advancing cancer treatment, positioning them alongside industry leaders targeting the ROR1 tumor antigen. Their bold move could be reshaping the competitive landscape in oncology research and development. Join us in celebrating these groundbreaking advancements in the biotech industry! 💼🔬 #Biotech #Innovation #Healthcare #Pharmaceuticals #AI #Oncology #ALS #ADCs

# Only put off until tomorrow what you are willing to die having left undone ## Seize the Opportunity: Invest in AbbVie Stock After Recent Parkinson's Study Success! Last week, AbbVie \(ABBV\) made a groundbreaking announcement that their pivotal phase III study evaluating the pipeline candidate, tavapadon, for treating early Parkinson's disease has successfully met the primary endpoint. This significant achievement comes after the inclusion of tavapadon into AbbVie's pipeline through the acquisition of neuroscience drugmaker Cerevel Therapeutics for approximately $8.7 billion in August 2024. AbbVie's positive Parkinson's study data showcases their commitment to advancing healthcare solutions and further solidifies their position as a leader in the pharmaceutical industry. With this remarkable development, investors have an exceptional opportunity to grow their portfolios while contributing to the improvement of patients' lives. Investing in AbbVie stock now will allow you to tap into the potential growth and profits generated from the success of tavapadon. By allocating funds from your Health Savings Account \(HSA\) towards this investment, you can benefit from both the financial gains and the satisfaction of supporting groundbreaking medical advancements. Don't miss out on the chance to be part of this transformative journey. Act now and consider investing in AbbVie stock with your HSA. Empower your financial future while making a positive impact on the world of healthcare. 📈💪 #hsa #investing #healthcare #health #family #wellness